Business ❯ Healthcare

Biotechnology

Pharmaceuticals Clinical Trials Gene Therapy Immunotherapy Regulatory Affairs Cell Therapy Therapeutics Product Development Vaccines Drug Development Gene Editing Research and Development Pharmaceutical Companies Genetic Testing Bluebird bio Inc. Contract Research Organizations Diagnostics Biologics Insulin Products Drug Delivery RNA Interference Complement Inhibitors Drug Discovery Genmab Immunotherapeutics Theranos Therapies Viking Therapeutics Genetic Medicine Oncology Gene Sequencing Clinical Research Company Announcements Genetics Regulatory Compliance Humacyte, Inc. Medical Devices Company Operations Market Trends

Danaher Rallies After Q3 Beat, Reaffirms 2025 Outlook and Sketches 2026 Growth Range

The beat reflected DBS execution with a pull‑forward of respiratory testing at Cepheid.

Recursion Pharmaceuticals Leaps 14% Ahead of Expected Early‑November Update

Rani Therapeutics and Chugai Sign Oral Biologics Collaboration Worth Up to $1.085 Billion

Bristol Myers Squibb Buys Orbital Therapeutics for $1.5 Billion to Push In Vivo CAR‑T Into Autoimmune Care

FDA Signals Openness to Accelerated Path for Lexeo’s Friedreich’s Ataxia Cardiac Gene Therapy

BioRestorative Prices $1.085 Million Direct Offering at $1.60 With Concurrent Warrants

Cramer Reiterates Skepticism on Recursion, Calls for Proof of Concept